Idéal Investisseur
Français English
CAC 40 : Market closed
8 365,01 pts
-0.05%


Last updated : 16/11/2026 - 17h14
🏠 Home   ➤    Stock news

Abivax shares slip back below €76.05, in the lower ranks of the SBF 120

The Paris-based biotech specialising in inflammatory diseases moves into negative territory as the close approaches, while its benchmark index remains virtually unchanged. The stock extends a difficult quarter and remains well below its long-term reference levels.


Abivax shares slip back below €76.05, in the lower ranks of the SBF 120

A decline brings the stock closer to its support at €76.05

Abivax shares fell 2.4% to €77.20 intraday and are among the largest decliners in the SBF 120, which is nonetheless flat. The price is approaching its support at €76.05, a level the stock had broken on 6 November before recovering in the following sessions. Resistance is at €84.35.

The stock remains below its 20-day moving average (a gap of 3.29%) and its 200-day moving average (a gap of 21.14%), illustrating the scale of the medium-term decline: it has lost nearly 25% over three months.

Abivax is a single company listed on two exchanges, in Paris and on the Nasdaq, where the ADS reflects the same stock, at a ratio of one share per ADS.

Short positions total 5.59% of the share capital

According to the disclosures reviewed, five funds hold a combined net short position of 5.59% of the share capital, up 0.24 points over one month, after 5.35% thirty days ago. This level indicates that a significant share of institutional investors remains positioned against the stock or is seeking to hedge its exposure.

The increase over the period remains modest, which does not allow it to be read as a sudden wave of distrust. To put the trend in context, the stock has fallen 5.8% over one month and nearly 25% over three months. The €76.05 level is the closest technical reference to the current price.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: S1 2026
Key reported figures
  • Net income: -165,9 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours